Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  DHAP regimen
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-7 of 7 for your search:
Start Over
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CSWOG0002, NCT01788137
Everolimus in Combination With DHAP in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: HD-R3i, NCT01453504
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CD-ON-MEDI-551-1088, NCT01453205
STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: STORM-2011, 2011-001491-20, NCT01653067
Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BIBLOS, NCT02055924
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Transplant BRaVE, NL40688.018.12, 2012-003097-45, NCT02280993
High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Phase: No phase specified
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 13/B/04, 2013-A00327-38, NCT01941680
Start Over